Floatz logo

Bortezomib

Recurrent Adult Brain Tumor

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

62 Active assets in the Recurrent Adult Brain Tumor cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 2BBB
Temsirolimus
M.D. Anderson Cancer Center
Phase 2BBB
Sorafenib
National Cancer Institute (NCI)
Phase 2BB
Bxcl501
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
Vorinostat
H. Lee Moffitt Cancer Center and Research Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Bortezomib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
71 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →